A phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, for treatment of psoriatic arthritis: Long-term (52-week) improvements in physical function

Authors
Category Primary study
ConferenceArthritis and Rheumatology
Year 2014
This article has no abstract
Epistemonikos ID: b3ec23003ae54faa2002188dba17d2eb269f4271
First added on: Apr 30, 2026